We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > nangibotide

News List

Inotrem gets clearance to launch phase 2 trial of Nangibotide in Covid-19 patients pharmaceutical-business-review
July 29, 2020
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced that it has obtained authorization to launch its phase IIa clinical trial in COVID-19 patients in France, Belgium and the USA.
US FDA fast tracks Inotrem’s nangibotide for septic shock pharmaceutical-technology
September 04, 2019
The US Food and Drug Administration (FDA) has awarded fast track designation to French biotechnology firm Inotrem’s nangibotide programme, which is being developed to treat septic shock.